The authors survey the ultrastructural organization of glutamatergic synapses by cryo-ET and image processing tools using two complementary experimental approaches. The first approach employs ...

Commenting on the Spinogenix glaucoma program, and his addition to the Company's SAB, Dr. Weinreb noted, "Glaucoma-related ...

SPG302 is a clinical stage, orally administered small molecule therapeutic with the unique ability to rapidly regenerate glutamatergic synapses. These synapses, a key feature of retinal circuitry ...

Our research supports that GluA4 subunit confers a minimal mechanism for activity-dependent AMPA-receptor regulation to facilitate plasticity during early development of glutamatergic synapses.

A wealth of data from histological, imaging, genetic and other studies implicate a loss of glutamatergic synapses in frontal cortex and other regions as a primary feature of schizophrenia ...

Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

New research provides evidence that synaptic NMDAR number and subunit composition are not static, but change dynamically in a cell- and synapse-specific manner during development and in response ...

Whereas the specific type and number of glutamate receptors at glutamatergic synapses must be precisely regulated, the mechanisms underlying glutamate receptor targeting and stabilization are not ...